Connect with us

Hi, what are you looking for?

Jewish Business News

Business

Four Deals of over $1 Billion Each helps Israeli Exits Reach $12.63 Billion

According to Ivc research center four large exits captured almost 65% of total exit value in 2018 • Excluding large deals, exit totaled $4.5 billion—lowest since 2014

Key facts:
• Four large exits captured almost 65% of total exit value
• Excluding large deals, exit value in 2018 totaled $4.5 billion—lowest since 2014
• Number of M&A deals dropped 20% in 2018 compared to 2017
• Eight Israeli IPOs at NASDAQ and ASX
• The number of non-VC backed exits decreased by 58%

According to IVC Research Center in 2018, exits activity reached $12.63 billion in 103 deals, including four large deals, each over $1 billion:
Orbotech – acquired by KLA-Tencor for $3.4 billion (Subject to closing);  Imperva – acquired by Thoma Bravo for $2.1 billion;  Mazor Robotics – acquired by Medtronic for $1.6 billion (Subject to closing);  SynaMedia (formerly NDS) – acquired by Permira for $1 billion

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.

The total number of exit deals slightly decreased to 103 compared to 133 in 2017. According to IVC–Meitar Exit Report, the decrease is due to a decrease of M&A deals of $20 million and below.

Shira Azran, Partner at Meitar Liquornik Geva Leshem Tal & Co.: “The aggregate value of the exits in 2018 was significant, approx. $12.63 billion. A closer look at the data reveals mixed trends. On the one hand, four exits exceeded $1 billion and these deals have become part of the industry. On the other hand, during 2018 we saw a decrease in the number of exits of private companies between $ 250 million and $ 1 billion.”

Azran added: “An examination of the investment data indicates an increase in 2018 in general, and in particular, the number of large-scale investments in growth companies increased significantly. For example, the number of companies raising amounts of more than $30 million, rose to a peak of 62 transactions in 2018. This combination of a significant increase in the volume of investments in growth companies and a relative stagnation in exits value, highlights the fact that Israel is building a strong and significant infrastructure of companies that in the coming years will examine their ability to reach an exit that reflects a significant return to investors”.

Azran also said that “examining worldwide trends, shows a trend of decrease in the number of transactions compared to an increase in overall value. This trend, in addition to consolidation of buyers, leads us to believe that in order to realize significant exit value buyers will be looking mainly for companies whose acquisition will lead to a significant impact on their activity. For certain companies this may mean that their right course of action will be to consolidate resources, thereby enabling a more significant fingerprint that will appeal to international buyers. ”

While VC-backed deals remained at stable levels in 2018, a significant drop of 58% was noted in the non-VC-backed exits.

2018 IPO and Buyout numbers retained their historical ranges. Five Israeli life science companies completed their IPO in the US, raising an aggregate of $246 million. Three Israeli companies completed an IPO in Australia, raising a modest $12 million.

M&A values in 2018 totaled $11.1 billion compared to $6.3 billion in 2017. M&A numbers dropped 20% from 111 to 89 transactions in 2018. The four large exits above $1 billion counterbalanced a decline in the number of exits in the range of $250 million to $1 billion, from five in 2016 and eight in 2017 to just three in 2018 (Excluding exits over $5 billion, public companies and divestitures).

Benzi Segev, CEO of IVC Research Center: “The Israeli start-up landscape in 2018 took another step in the global direction of more money funneled into less deals. This pattern was noted on both sides of the tech deal activity—M&A and funding. Looking 12 to 18 months ahead, the fundamentals for long term growth already exist—amounts and numbers of large investments are on the rise, but it remains to be seen if the local scene could use these resources to grow.”

The average ratio continuing to decline mostly in non-VC-backed companies, from 5.19 in 2017 to 4.79 in 2018. The VC-backed ratio declined to 2.61 compared to 2.92 in 2017.

According to the IVC-Meitar Exit Report, in 2018 there were 34 VC-backed companies reaching an exit after more than five years of activity, similar to the level in the last 5 years for VC-backed exits. However, the number of non-VC-backed companies that reached an exit in less than 5 years since establishment decreased nearly 60% in 2018, to only 15, compared to 34 and 36 in 2016 and 2017, respectively.

Exits by Sector and Technology Clusters

In 2018, the number of life sciences companies with exit activity continued to grow (24 deals including 7 IPOs). Exit values kept to the same level as 2017, reaching $2.98 billion.
While the number of deals in the IT & software sector remains stable, the value of 2018 exits increased to $4.49 billion from $3.31 billion in 2017.

AI (Artificial Intelligence) exit values soared in 2018 mostly due to the Datorama deal ($850m), reaching $1.15 billion, almost four-times higher compared to $307 million in 2017. This increase positively affected the AI exit ratio, 7.02 in 2018 compared to 2.11 in 2017. The number of AI exits remains in historical figures.

Cyber security exit values in 2018 set a record—$2.81 billion in 12 deals compared to $1.35 billion in 14 deals in 2017. The cyber exit ratio dramatically increased to 14.91 compared to 3.89 in 2017.

 

Newsletter



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Life-Style Health

Medint’s medical researchers provide data-driven insights to help patients make decisions; It is affordable- hundreds rather than thousands of dollars

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

History & Archeology

A groundbreaking discovery in the Manot Cave in the Western Galilee, Israel has unearthed the earliest evidence in the Levant (and among the world's...